Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A preclinical platform for assessing anti-tumor effects and systemic toxicities of cancer drug targets

ABSTRACT: A preclinical platform for assessing anti-tumor effects and systemic toxicities of cancer drug targets

PROVIDER: PRJNA807304 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18038501.fastq.gz	Fastqsanger.gz
	SRR18038502.fastq.gz	Fastqsanger.gz
	SRR18038503.fastq.gz	Fastqsanger.gz
	SRR18038504.fastq.gz	Fastqsanger.gz
	SRR18038505.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

A preclinical platform for assessing anti-tumor effects and systemic toxicities of cancer drug targets

Project description:Anti-cancer drug development campaigns often fail due to an incomplete understanding of the therapeutic index differentiating the efficacy of the agent against the cancer and its on-target toxicities to the host. To address this issue, we established a versatile preclinical platform in which genetically defined cancers are produced using somatic tissue engineering in transgenic mice harboring a Doxycycline-inducible short hairpin RNA against the target of interest. In this system, target inhibition is achieved by addition of doxycycline, enabling simultaneous assessment of efficacy and toxicity in the same animal. As proof-of-concept, we focused on CDK9 — a cancer target whose clinical development has been hampered by compounds with poorly understood target specificity and unacceptable toxicities. We systematically compared phenotypes produced by genetic Cdk9 inhibition to those achieved using a recently developed highly specific small molecule CDK9 inhibitor and found that both perturbations led to robust anti-tumor responses. Remarkably, non-toxic levels of CDK9 inhibition could achieve significant treatment efficacy, and dose-dependent toxicities produced by prolonged CDK9 suppression were largely reversible upon Cdk9 restoration or drug withdrawal. Overall, these results validate a versatile in vivo target validation platform that can be employed for rapid triaging of therapeutic targets and lend support to efforts aimed at advancing CDK9 inhibitors for cancer therapy.

2022-03-30 | GSE196783 | GEO

A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.

Project description:Anticancer drug development campaigns often fail due to an incomplete understanding of the therapeutic index differentiating the efficacy of the agent against the cancer and its on-target toxicities to the host. To address this issue, we established a versatile preclinical platform in which genetically defined cancers are produced using somatic tissue engineering in transgenic mice harboring a doxycycline-inducible short hairpin RNA against the target of interest. In this system, target inhibition is achieved by the addition of doxycycline, enabling simultaneous assessment of efficacy and toxicity in the same animal. As proof of concept, we focused on CDK9—a cancer target whose clinical development has been hampered by compounds with poorly understood target specificity and unacceptable toxicities. We systematically compared phenotypes produced by genetic Cdk9 inhibition to those achieved using a recently developed highly specific small molecule CDK9 inhibitor and found that both perturbations led to robust antitumor responses. Remarkably, nontoxic levels of CDK9 inhibition could achieve significant treatment efficacy, and dose-dependent toxicities produced by prolonged CDK9 suppression were largely reversible upon Cdk9 restoration or drug withdrawal. Overall, these results establish a versatile in vivo target validation platform that can be employed for rapid triaging of therapeutic targets and lend support to efforts aimed at advancing CDK9 inhibitors for cancer therapy.

| S-EPMC9169916 | biostudies-literature

Platform for assessing immune response signatures in healthy human subjects

Project description:Platform for assessing immune response signatures in healthy human subjects

| PRJNA422946 | ENA

Platform for assessing immune response signatures in healthy human subjects

Project description:Platform for assessing immune response signatures in healthy human subjects

| PRJNA422947 | ENA

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

Project description:Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

| PRJNA605423 | ENA

Ex Vivo Lung Perfusion as a Human Platform for Preclinical Small Molecule Testing

Project description:Ex Vivo Lung Perfusion as a Human Platform for Preclinical Small Molecule Testing

| PRJNA486099 | ENA

Engineering CAR-NK cells to secrete IL15 sustains their anti-AML functionality, but is associated with systemic toxicities

Project description:Engineering CAR-NK cells to secrete IL15 sustains their anti-AML functionality, but is associated with systemic toxicities

| PRJNA765022 | ENA

Genome-wide predictors of treatment-related toxicities

Project description:Genome-wide predictors of treatment-related toxicities

| PRJNA398305 | ENA

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

Project description:Although immunotherapy has revolutionized cancer treatment, only a subset of patients demonstrates durable clinical benefit. Definitive predictive biomarkers and targets to overcome resistance remain unidentified, underscoring the urgency to develop reliable immunocompetent models for mechanistic assessment. Here we characterize a panel of syngeneic mouse models representing a variety of molecular and phenotypic subtypes of human melanomas and exhibiting their diverse range of responses to Immune Checkpoint Blockade (ICB). Comparative analysis of genomic, transcriptomic and tumor-infiltrating immune cell profiles demonstrated alignment with clinical observations and validated the correlation of T-cell dysfunction and exclusion programs with resistance. Notably, genome-wide expression analysis uncovered a Melanocytic Plasticity Signature (MPS) predictive of patient outcome in response to ICB, suggesting that the multipotency and differentiation status of melanoma can determine ICB benefit. Our comparative preclinical platform recapitulates melanoma clinical behavior and can be employed to identify new mechanisms and treatment strategies to improve patient care.

2020-06-01 | GSE144946 | GEO

Genetic Susceptibility and Biomarkers of Platinum-Related Toxicities

Project description:Genetic Susceptibility and Biomarkers of Platinum-Related Toxicities

| PRJNA475829 | ENA